FDA Panel Shoots Down Intellipharma Opioid

Jul 26, 2017

A U.S. FDA panel of independent advisers said there was not enough evidence to support the approval of Toronto-based Intellipharmaceutics International's long-acting opioid painkiller, according to a Reuters article.

The painkiller was developed as an abuse-deterrent version of Purdue Pharma's OxyContin, which already has tamper-resistant properties. The drug has a blue dye that is emitted if the tablet is manipulated, which could help identify abusers, and a nasal irritant to discourage misuse, the story said.

Read the full article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments